2009

21-40 of 93 < first | | | last >
  • Podcast: Online TOC and Real-Time Release on the Global Stage

    In the second of this two-part series, Jonathan Yourkin, pharmaceutical market manager with GE Analytical Instruments, provides insight on navigating the subtle, and sometimes dramatic, differences between pharmacopeia and regulators in the U.S. and abroad in regards to the use of online TOC. Yourkin also shares best practices for applying TOC to PAT applications and real-time product release.

    06/15/2009
  • Bio in Brazil: Positioned for Growth

    Biominas Foundation CEO, Eduardo Soares discusses how Brazil is prepping for growth in BIO and looking for guidance from other regulatory agencies.

    06/01/2009
  • Sanofi Opens Up, Looking for a Few Good Partners

    Sanofi-Aventis is undergoing a major internal shift, opening itself up more and more to external partnerships and “access to innovation.” Senior VP Jean-Claude Muller talks about making alliances work, and how Sanofi’s new bio plant outside Paris figures in the mix.

    06/01/2009
  • Symyx QbD Strategy

    Symyx Technology's Eric Carlson and Matthew Pino discuss how Symyx's new CDMO capability conforms with the industry's Quality by Design and automation needs.

    06/01/2009
  • A CMO’s Work is Never Done, Even in Academia

    Out of necessity, CMO’s today must be incredibly nimble, flexible, and aggressive. Nebraska-Lincoln’s Mike Meagher shares secrets of navigating a market in which the future is always uncertain, and every client demands immediate attention.

    06/01/2009
  • Expanded Bed Chromatography: “Rhobust”, Flexible

    Expanded bed chromatography, not new to pharma, can process unclarified feedstocks simply and flexibly, with disposable tubing that eliminates the need for CIP. Rob Noel of Upfront Chromatography A/S shares the ins and outs of his company’s Rhobust system.

    06/01/2009
  • Women In Bio: Get Connected

    Sr. Digital Editor, Michele V. Wagner discusses the opportunities for women in the life sciences with Women In Bio's President Elect, Lynn Johnson Langer, and President Emeritus, Robbie Melton.

    06/01/2009
  • Wyeth BioPharma: Pfizerized or Not?

    Wyeth SVP Michael Kowolenko rebuts the idea that Pfizer will be detrimental to Wyeth BioPharma and its continuous improvement culture.

    06/01/2009
  • Optimizing Bioprocessing: Artelis Gets Intense

    The iCellis chromatography system provides high-density (a million-plus cells per mL) bioprocessing combined with a single-use approach. Nicolas Havelange gives us the cook’s tour.

    06/01/2009
  • Progressive Peptides: Unigene Pushes New Methods, New Deliveries

    Unigene Labs’ proprietary technology accelerates peptide yield and purity by secreting the product of interest into a media; the company is also paving the way to oral and nasal delivery of peptide therapies, explains VP of Product Development Jim Gilligan.

    06/01/2009
  • A World Beyond ICH: WHO, ISO Must Figure Prominently in Harmonization

    Regulatory harmonization has made great strides, but if efforts are to become truly global the World Health Organization must be involved. In this audio interview, Birgitte Holst, Manager of Manufacturing Science & Quality at Novo Nordisk, discusses pharmacopeia, terminology, anticounterfeiting, and more.

    05/28/2009
  • Puerto Rico 2.0: Repositioning an Industry to Restore a Competitive Edge

    No one needs to tell Puerto Rico the global pharmaceutical market has changed. The island is in the midst of a makeover that will focus on biotech, generics, and outsourcing its 40-plus years of expertise with the aim of keeping the island relevant to pharma. INDUNIV executive director Ivan Lugo talks strategy.

    05/28/2009
  • It’s Good to Be a Scientist: Life Sciences Job Market Holding Firm

    The turmoil in life sciences and merging of small- and large-molecule manufacturers only enhances the attractiveness of experienced scientists and engineers, says Kurt Moore, president of TalentWRx staffing agency. For those whose careers are in flux, making the most of a temporary position may open doors to something more permanent.

    05/28/2009
  • Microfluidics to Eliminate Animal Trials

    Dublin-based Cellix is using microfluidics drug screening to simulate human capillaries and circumvent the need for costly and controversial animal trials. CEO Vivienne Williams explains.

    05/12/2009
  • Automated EH&S: Move Away from Paper

    The right software can help manufacturers save time and money, and improve environmental health. Dan Gallagher of Cork, Ireland's EHA Soft discusses the challenges of maintaining environmental health and safety compliance with Senior Digital Editor Michele Vaccarello Wagner.

    05/12/2009
  • Increasing Bioavailability for Oral/Solid Dosage Forms

    Does your drug really need the needle? Senior Digital Editor Michele Vaccarello Wagner sits down with Merrion Pharmaceuticals CEO John Lynch at Trinity College Dublin to discuss the GIPET and GIRES technology for developing oral forms of drugs that were previously injection-based.

    05/12/2009
  • Keys to Contract Manufacturing: Flexibility and Localization

    Jim Kernan, Joint Managing Director of Nenagh Ireland's PharmaFlow, addresses the importance of flexibility and localization of small-to-midsize batch contract manufacturing and discusses why companies should look to Ireland as a port of entry to Europe.

    05/12/2009
21-40 of 93 < first | | | last >